Cargando…

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity. The reliable models that might predict weight reducing potential at the individual level have not been identified yet. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensterle, Mojca, Rizzo, Manfredi, Haluzík, Martin, Janež, Andrej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063254/ https://www.ncbi.nlm.nih.gov/pubmed/35503498 http://dx.doi.org/10.1007/s12325-022-02153-x

Ejemplares similares

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications
por: Jensterle, Mojca, et al.
Publicado: (2021)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

The Role of Physicians’ Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus
por: Janež, Andrej, et al.
Publicado: (2022)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly
por: Herman, Rok, et al.
Publicado: (2022)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
por: Jensterle, Mojca, et al.
Publicado: (2021)

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives
por: Jensterle, Mojca, et al.
Publicado: (2022)

SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age
por: Podbregar, Ana, et al.
Publicado: (2020)

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
por: Jensterle, Mojca, et al.
Publicado: (2019)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Assessment of Eating Disorders and Eating Behavior to Improve Treatment Outcomes in Women with Polycystic Ovary Syndrome
por: Kolnikaj, Tea Shehu, et al.
Publicado: (2022)

Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome
por: Herman, Rok, et al.
Publicado: (2020)

Endocrine disorders after heart transplantation: national cohort study
por: Rakusa, Matej, et al.
Publicado: (2020)

Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
por: Herman, Rok, et al.
Publicado: (2023)

Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
por: Hropot, Tim, et al.
Publicado: (2023)

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects
por: Mastnak, Lara, et al.
Publicado: (2023)

INDIVIDUALIZATION OF CUSTOM COMPOUNDED HORMONE THERAPY IN A PATIENT WITH CHEMOTHERAPY INDUCED PREMATURE OVARIAN INSUFFICIENCY AND IMPAIRED LIVER FUNCTION – CASE REPORT
por: Franić, Damir, et al.
Publicado: (2019)

Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
por: Kravos, Nika Aleksandra, et al.
Publicado: (2021)

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport
por: Herman, Rok, et al.
Publicado: (2022)

SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
por: Janež, Andrej, et al.
Publicado: (2021)

Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues
por: Rizvi, Ali A., et al.
Publicado: (2021)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

SLC6A4 5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome
por: Šenk, Barbara, et al.
Publicado: (2018)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
por: Kalra, Sanjay, et al.
Publicado: (2019)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Effects of Mindfulness-Based Therapy on Clinical Symptoms and DNA Methylation in Patients with Polycystic Ovary Syndrome and High Metabolic Risk
por: Dema, Hana, et al.
Publicado: (2023)

MON-220 Androstendione Affects Endometrial Gene Expression Profile During Window of Implantation in Obese Infertile Women with PCOS
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study
por: Podbregar, Ana, et al.
Publicado: (2021)

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway
por: Wei, Liufeng, et al.
Publicado: (2022)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
por: Ferjan, Simona, et al.
Publicado: (2019)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b3iiku5an00dvoofkfknjl7662